Evidence map›Paper›PMID 39751895›Full record

ArticleInternational journal of colorectal disease2025

Impact of adjuvant chemotherapy on survival in ypT0-2 N0 rectal cancer.

Mohamed Osama Alorabi, Abdelrahman Gouda, Mohammed Abdeen, Ahmed Said, Moamen Abdelaal, Reem Eid, Maha Yahia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of colorectal disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohamed Osama AlorabiClinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt. Mohamed_Alorabi@med.asu.edu.eg.
Abdelrahman GoudaClinical Oncology Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
Mohammed AbdeenClinical Oncology Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
Ahmed SaidClinical Oncology Department, Faculty of Medicine, Aswan University, Aswan, Egypt.
Moamen AbdelaalRadiation Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Reem EidBiostatics & Epidemiology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Maha YahiaMedical Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe role of adjuvant chemotherapy in rectal cancer patients downstaged to ypT0-2 N0 after neoadjuvant chemoradiotherapy (CRT), and surgery is still debated. This study investigates the impact of adjuvant chemotherapy on survival outcomes in this patient population.

methodsThis retrospective study analyzed hospital records of rectal cancer cases from Shefa Al Orman Cancer Hospital between January 2016 and December 2020, focusing on patients downstaged to ypT0-2 N0 after neoadjuvant CRT and surgery. Patients were divided into two groups based on whether they received adjuvant chemotherapy. Baseline characteristics, DFS, and OS were compared, and survival factors were analyzed using univariate and multivariate Cox regression.

resultsEighty-five patients met the inclusion criteria; 55 received adjuvant chemotherapy, and 30 did not. The median age was 52, but those receiving adjuvant therapy were younger (47 vs. 60 years, P = 0.006). No significant differences were observed in sex, tumor location, or pathology between groups. Although adjuvant chemotherapy showed a trend toward better 3-year DFS (89.5% vs. 81.9%, P = 0.153) and OS (88.1% vs. 84.6%, P = 0.654), these differences were not statistically significant. Univariate and multivariate analyses confirmed no significant effect of adjuvant chemotherapy on DFS or OS, nor were any other variables significantly associated with survival.

conclusionAdjuvant chemotherapy did not significantly improve DFS or OS in rectal cancer patients downstaged to ypT0-2 N0 following neoadjuvant CRT and surgery. Further studies are needed to define the role of adjuvant therapy in this group.

Indexed as

Neoplasm StagingRectal NeoplasmsAdultAgedChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesTreatment OutcomeDownstagingingPathological responseRectal adenocarcinomaSurvival outcomes

Identifiers

PMID39751895
PMCPMC11698752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.